USAID Global Accelerator to End TB

Speeches Shim

Global Accelerator to End TB
From 2018-2022, 40 million people will be on treatment for TB.

 

ACCELERATING ACTION ON TB TOWARDS ACHIEVING 40X22

USAID leads the U.S. Government’s global tuberculosis (TB) efforts, working with agencies and partners around the world to reach every person with TB, cure those in need of treatment, and prevent the spread of new infections.

In September 2018, the United Nations General Assembly High Level Meeting (UNHLM) on TB set the stage for high-level attention and action on TB. This meeting established the ambitious target of diagnosing and enrolling an additional 40 million people on TB treatment by 2022 (commonly referred to as 40x22), with a focus on countries with the highest TB burden, and enrolling 30 million on TB preventive therapy (commonly referred to as 30x22).

USAID supports countries in reaching the global targets of diagnosing and enrolling 40 million people on TB treatment and enrolling 30 million on TB preventive therapy by 2022.

THE GLOBAL ACCELERATOR TO END TB

Launched at the 2018 UNHLM, USAID’s Global Accelerator to End TB increases commitment from, and builds the capacity of, governments, civil society, and the private sector to accelerate national progress in reaching the global targets set forth at the UNHLM. The Accelerator focuses on countries with high burdens of TB where the Agency can align with local communities and partners to deliver performance-based results. To ensure the Accelerator’s effectiveness and increased transparency, USAID uses standardized data collection and performance-based indicators that align with the targets.

The Accelerator ensures that USAID is fighting to end TB efficiently and effectively by building local commitment and capacity with a focus on locally generated solutions that tailor the Agency’s TB response and combat stigma and discrimination.

Through the Accelerator, USAID continues to promote prevention strategies, improve patient-centric care, strengthen service delivery, and provide new TB diagnostics and drugs in the fight against TB. To address the specific challenges of MDR-TB patients, USAID is expanding the availability of new MDR-TB drugs and regimens that save lives, as well as investing in pivotal clinical trials. These efforts ensure that people with TB, especially vulnerable populations and those living in poverty, are at the forefront of interventions at all levels of the health system.

Through redefining our development relationship with partner governments, strengthening local institutions, and promoting systemic change, the Accelerator remains increasingly relevant in building countries’ local capacities and commitment to address TB. Since its launch, the Accelerator has made significant progress in three key areas to support reaching country TB targets:

Icon: Hands clasped together
PARTNERING WITH MINISTRIES OF HEALTH:
USAID Missions have signed partnership statements with Ministries of Health in 18 USAID TB countries. The statements are the basis for increased collaboration and coordination on interventions to reach the UNHLM targets. To support the commitments made in these statements, USAID is developing intervention-specific TB commitment grants with the Ministries.
 
Icon: Figures linked together to represent community
Sustainable Technical Support
USAID has embedded advisors in priority countries to build National TB Programs’ capacities. Through mentorship and technical expertise, these advisors help improve systems and expand interventions for more sustainable and focused TB programming.
 
Icon: A location marker
Locally Generated Solutions
USAID has made direct awards to 35 local organizations, including faith-based groups and many new partners. These awards support grassroots solutions and drive community generated results toward National TB Strategic Plan and UNHLM targets.
 

Last updated: February 24, 2021

Share This Page